Long-term effects of an oral iron chelator, deferasirox, in hemodialysis patients with iron overload

Figures & data

Table 1. Clinical characteristics of eight HD patients with transfusional iron overload receiving iron chelation therapy with DFX

Table 2. Comparison of the effect of DFX in HD patients with iron overload

Table 3. Metabolic changes of iron regulation and response of hematopoiesis before and after administration of DFX in HD patients with iron overload

Figure 1. Percentage of the change of serum ferritin level after DFX treatment over time.

Figure 2. Change in (A) hematocrit (Hct), (B) average EPO dosage, (C) average blood transfusion, and (D) serum ferritin level monthly before and after DFX treatment analyzed with GEE model. Note: The boxes represent the 25th and 75th percentiles, while the whiskers correspond to the 10th and 90th percentiles. The medians are connected.

Ifudu O, Macey LJ, Friedman EA. Resurgence of blood transfusion therapy in erythropoietin treated hemodialysis patients. ASAIO J. 1995;41:M426–30.

 PubMedGoogle Scholar

National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services. [Accessed 2013 May 20] Common terminology Criteria for Adverse Events (CTCAE) Version 4.0. Published May 28, 2009; Revised Version 4.03 June 14, 2010 (Vol. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5×7.pdf).

 Google Scholar